



FOR IMMEDIATE RELEASE

SpermSep European Patent Granted

SYDNEY, AUSTRALIA – 8th March 2010 – NuSep (ASX: NSP) is pleased to announce that the European patent for the SpermSep has now been granted.

This is an important step in the commercial development of the SpermSep as it gives NuSep exclusive rights to manufacture and sell the SpermSep in Europe. NuSep now has granted SpermSep patents in both Australia and Europe. The Company has pending a patent application in America.

The Market

Sperm separation is a fundamental requirement for all Assisted Reproductive Technology (ART) treatments and the use of ART is growing rapidly as couples plan to have babies into their 30s and 40s when natural fertility begins to decline. In Australia the IVF market is worth around \$170m and in the US it is a \$3 billion market. The SpermSep instrument addresses approximately 1-2% of these markets. In the 2006 report by the International Committee for Monitoring the Assisted Reproductive Technologies (ICMART) the total number of ART cycles undertaken in the world was estimated at 1 million a year. Based on this, NuSep estimates the total current SpermSep consumables market at \$A45m per annum.

Advantage of the SpermSep over the existing process

The SpermSep offers a number of advantages over the existing Density Gradient Centrifugation (DGC) separation process as shown in a phase 1 clinical trial held at Westmead Fertility Clinic in 2008. These include:

	SpermSep	DGC
Separation Time	5 min	45 min
DNA damage	lower	higher
Sample Cross Contamination	very low	Yes
Pregnancies/Live Births ¹	3/3	0/0

Recent Developments

A number of developments have occurred over the last few months including the development of a disposable cartridge to eliminate contact between the instrument and the sample.

¹ Westmead Clinical trial of 18 couples, 9 using the SpermSep and 9 using the DGC process. This clinical trial was completed in late 2008.

NuSep Ltd

324 Burns Bay Rd
Lane Cove NSW 2066

Postal Address

P.O. Box 823
Lane Cove NSW 1595

Contact Details

Telephone +61 2 8197 3377
Facsimile +61 2 9427 8614

Email info@nusep.com

Web www.nusep.com
ABN 33 120 047 556

Time to Market

NuSep expects to undertake a final pre market clinical trial this year and the first commercial sales are also budgeted to occur in the second half of this year.

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteoIQ software enabling NuSep to offer a total Proteomics solution from ***Fraction to Function***. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

- **Gels** – NuSep manufactures and sells precast gels including the innovative **NUView** Gels, which can be visualised 2 minutes after use.
- **Separation Instruments** – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF and is expected to undergo clinical trials later this year.
- **Proteomics Software** – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
- **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

Contact:
Prakash Patel
Chief Financial Officer & Company Secretary
+61 2 8197 3377
prakash.patel@nusep.com